BioCardia (BCDA) director reports Form 4 stock option grant of 12,000 shares

Rhea-AI Filing Summary

BioCardia, Inc. reported an insider equity award to one of its directors. On 12/08/2025, the director received a stock option to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. The option vests and becomes fully exercisable on the one-year anniversary of the grant date, so long as the director continues as a service provider through that date, and it expires on 12/08/2035. Following this grant, the director beneficially owns 15,729 derivative securities, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Facteau Bill

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.37	12/08/2025		A		12,000		(1)	12/08/2035	Common Stock	12,000	$0	15,729	D

Explanation of Responses:

1. One hundred percent of the shares are subject to the option vesting and becoming exercisable on the one-year anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.

	/s/ David McClung, by power of attorney	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioCardia (BCDA) report in this Form 4?

A BioCardia, Inc. director reported receiving a stock option covering 12,000 shares of BioCardia common stock in an equity award transaction dated 12/08/2025.

What is the exercise price of the BioCardia (BCDA) stock options granted?

The director’s stock option has an exercise price of $1.37 per share for 12,000 shares of BioCardia common stock.

When do the BioCardia (BCDA) director stock options vest and become exercisable?

The filing states that 100% of the shares under the option vest and become exercisable on the one-year anniversary of the grant date, provided the director continues as a service provider through that date.

When do the newly granted BioCardia (BCDA) stock options expire?

The stock options granted to the director are scheduled to expire on 12/08/2035.

How many derivative securities does the BioCardia (BCDA) director own after this transaction?

After the reported grant, the director beneficially owns 15,729 derivative securities, held in direct ownership.

What is the reporting person’s relationship to BioCardia (BCDA)?

The reporting person is identified as a Director of BioCardia, Inc. on the Form 4.